CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
FACBC PET-CT +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02830880
NCT02830880Phase 2Completed
CompareCT.gov

Investigation of Therapy Response With Amino Acid Analogue Transport PET Imaging

Emory University·interventional·Posted Jul 13, 2016·Updated Jan 7, 2020

In Brief

A Phase 2 clinical trial evaluating FACBC PET-CT and MRI, CT, or Bone Scan for Prostate Cancer. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of this study is to assess if using anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment. Investigators will enroll participants whose cancer has been treated with hormone therapy and now the cancer is not responding to the treatment (castration -resistant), and so therefore will be started on chemotherapy. Investigators aim to enroll thirty participants in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsBlue Earth Diagnostics, Nihon Medi-Physics Co., Ltd.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 13, 2016
Enrollment StartJul 1, 2016
Primary CompletionDec 1, 2018
Study CompletionSep 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.0 years ago

Interventions

FACBC PET-CTdrug

Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.

MRI, CT, or Bone Scanother

Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.